1 Reason to Buy Biogen Stock, and 1 Reason to Sell
Biogen (NASDAQ: BIIB) has been one of the more notable names in the biotech industry in the past four years -- and not always for the best of reasons. U.S. approval of Biogen's Aduhelm for treating Alzheimer's disease (AD) turned out to be a bit of a flop as the medicine isn't generating anywhere near the kinds of sales the drugmaker hoped to see.
However, newer developments are making Biogen look like a better prospect. But does the company's upside now outweigh its risks? Let's consider one reason the answer might be yes, and one reason to be wary of Biogen's future.
In early January, Biogen and its longtime collaborator in the development of AD therapies, Japan-based Esai, reported that the U.S. Food and Drug Administration (FDA) had granted accelerated approval to Leqembi, which is indicated to treat early AD patients.
Source Fool.com
